Department of Dermatology, University of Florida, Gainesville, Florida.
Dermatol Ther. 2019 Sep;32(5):e12999. doi: 10.1111/dth.12999. Epub 2019 Jun 30.
Solid organ and stem cell transplant recipients have an increased risk of developing cutaneous infections, which often are refractory to conventional treatment (Euvrard et al., Journal of the American Academy of Dermatology, 2001, 44, 932-939). Molluscum contagiosum, a common self-limited disease primarily affecting children, can be more severe and unresponsive to therapy in transplant patients (Gardner & Ormond, Clinical and Experimental Dermatology, 2006, 31, 452-453). Candida immunotherapy has been widely used for the treatment of warts, and recently its application has been expanded to include treatment of symptomatic molluscum in pediatric patients (Enns & Evans, Pediatric Dermatology, 2011, 28, 254-258; Maronn et al., Pediatric Dermatology, 2008, 25, 189-192). However, to our knowledge there have been no reports in the literature of its utility in the setting of adult transplant or immunocompromised patients. Herein, we report a case of successful treatment of refractory molluscum contagiosum in a stem cell transplant patient with Candida immunotherapy.
实体器官和干细胞移植受者发生皮肤感染的风险增加，而这些感染通常对常规治疗有抗性（Euvrard 等人，《美国皮肤病学会杂志》，2001 年，44 期，932-939）。传染性软疣，一种主要影响儿童的常见自限性疾病，在移植受者中可能更严重且对治疗无反应（Gardner 和 Ormond，《临床与实验皮肤病学》，2006 年，31 期，452-453）。咪喹莫特免疫疗法已广泛用于治疗疣，最近其应用范围已扩大到包括治疗儿科患者有症状的传染性软疣（Enns 和 Evans，《儿科皮肤病学》，2011 年，28 期，254-258；Maronn 等人，《儿科皮肤病学》，2008 年，25 期，189-192）。然而，据我们所知，在成人移植或免疫功能低下患者的背景下，尚无其疗效的文献报道。在此，我们报告了一例利用咪喹莫特免疫疗法成功治疗干细胞移植患者难治性传染性软疣的病例。
